Summary by Moomoo AI
The Vanguard Group has filed an amended Schedule 13G/A with the Securities and Exchange Commission (SEC) on February 13, 2024, indicating a change in their holdings of Novavax Inc. common stock. As of December 29, 2023, The Vanguard Group reported an aggregate beneficial ownership of 14,560,054 shares of Novavax, which represents 12.26% of the company's class of common stock. The filing, which is an update to previous disclosures, shows that The Vanguard Group has sole dispositive power over 14,304,541 shares and shared dispositive power over 255,513 shares, with shared voting power on 154,553 shares. The Vanguard Group, based in Pennsylvania, has stated that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Novavax Inc.